Detalhe da pesquisa
1.
First-in-Man Trial of SiO2 Inert-Coated Bare Metal Stent System in Native Coronary Stenosisã- The AXETIS FIM Trial.
Circ J
; 82(2): 477-485, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28717068
2.
Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
Am Heart J
; 167(2): 133-40, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24439973
3.
Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?
Expert Rev Med Devices
; 14(5): 325-334, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28402204
4.
Coronary Artery Vessel Healing Pattern, Short and Long Term, After Implantation of the Everolimus-Eluting Bioresorbable Vascular Scaffold.
J Am Heart Assoc
; 4(11)2015 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553215
5.
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial.
EuroIntervention
; 15(7): 603-606, 2019 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31147304